Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Table 2 Genotype and allele frequencies for SNP in VEGFR2 loci for patients treated with sorafenib and/or bevacizumab, with or without other agents

Allelic variant	N	Genotype frequencies, N (%)			Allelic frequencies
		Wt	Het	Var	p	q
VEGFR2 H472Q	170
C*	140	82	50	8	0.76	0.24
AA*	17	12	5	0	0.85	0.15
Others	13	9	4	0	N/A	N/A
VEGFR2 V297I	170
C*	140	114	25	1	0.9	0.1
AA*	17	9	6	2	0.71	0.29
Others	13	8	5	0	N/A	N/A

* Genotyping information was not available for n = 7 Caucasians and n = 1 African American included in subsequent analyses.
C: Caucasians, AA: African-Americans, Others: Hispanic or Asians, Wt: wild-type genotype, Het: heterozygous genotype, Var: homozygous variant genotype, p and q are standard Hardy-Weinberg nomenclature for allele frequencies.

ISSN: 1756-9966